Abstract Number: 1236 • 2019 ACR/ARP Annual Meeting
Subcutaneous or Oral Methotrexate Exposure and Response to Pegloticase in Uncontrolled Gout Patients in a Community Rheumatology Practice
Background/Purpose: Pegloticase is an infused biologic for uncontrolled gout patients that is highly effective but can cause anti-drug antibodies that lead to a lack of…Abstract Number: 1237 • 2019 ACR/ARP Annual Meeting
Treatment with OLT1177™, an Oral NLRP3 Inflammasome Inhibitor, Reduces Systemic Inflammation During Gout Flares in Humans
Background/Purpose: Gout flares are characteristically mediated by the pro-inflammatory cytokine interleukin (IL)-1β. Uptake of monosodium urate (MSU) crystals by macrophages activates the nucleotide-binding domain and…Abstract Number: 1240 • 2019 ACR/ARP Annual Meeting
A Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Anakinra in Difficult-To-Treat Acute Gouty Arthritis: The anaGO Study
Background/Purpose: In gout, urate crystals deposited in and around joints trigger episodes of acute arthritis, mediated by the proinflammatory cytokine IL-1β. In uncontrolled studies, the…Abstract Number: 1855 • 2019 ACR/ARP Annual Meeting
Evaluating the OMERACT Definitions of Ultrasound Gout Structural Lesions in the Diagnosis of Gout
Background/Purpose: To evaluate ultrasound (US) as a diagnostic tool for gout with positive urate crystal microscopy as the gold standard, using the OMERACT US working…Abstract Number: 1860 • 2019 ACR/ARP Annual Meeting
Using Electronic Visits (E-Visits) to Achieve Goal Serum Urate Levels in Patients with Gout in a Rheumatology Practice: A Pilot Study
Background/Purpose: Gout is a highly prevalent form of inflammatory arthritis associated with increased morbidity and mortality, and the burden of gout on the healthcare system…Abstract Number: 1937 • 2019 ACR/ARP Annual Meeting
Mononuclear Leukocyte DNA Methylome Imprinting of Networked Signaling and Immunity Regulatory Pathways in Gout
Background/Purpose: Gout encompasses acute arthritis flares mediated by innate autoinflammatory responses to urate crystals, chronic granulomatous tophi, and synovitis promoting bone erosion and soft tissue…Abstract Number: 2047 • 2019 ACR/ARP Annual Meeting
Time-trends in Opioid Use Hospitalizations in Common Musculoskeletal Conditions: Gout, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia, and Low Back Pain
Background/Purpose: Rates of opioid abuse and associated mortality is a problem of epidemic proportion in the U.S. To our knowledge, limited data are available on…Abstract Number: 2050 • 2019 ACR/ARP Annual Meeting
Association of Gout with Vitamin D: A Population-Based Study
Background/Purpose: Prior research showed conflicting results about the association of vitamin D with gout. We aimed in this study to quantify vitamin D levels in…Abstract Number: 2051 • 2019 ACR/ARP Annual Meeting
Factors in Achieving Serum Uric Acid Target and the Occurrence of Gouty Arthritis: A Cross-sectional Study Based on Japanese Health Insurance Claim Data
Background/Purpose: The number of gout attacks can be reduced by achieving and maintaining serum uric acid (sUA) at or below 6.0 mg/dL, a level uniformly…Abstract Number: 2053 • 2019 ACR/ARP Annual Meeting
Risk of Non-vertebral Fracture in Gout Compared to Rheumatoid Arthritis
Background/Purpose: Gout is a common inflammatory arthritis, characterized by hyperuricemia leading to crystallization of uric acid in joints. Proinflammatory cytokines have been known as an…Abstract Number: 2054 • 2019 ACR/ARP Annual Meeting
Epidemiology of Gout in South Korea with the National Health Insurance Corporation Database
Background/Purpose: Gout is the most common inflammatory arthritis that results from chronic elevation of uric acid levels above the saturation point for monosodium urate crystal…Abstract Number: 2058 • 2019 ACR/ARP Annual Meeting
Pharmacoepidemiology of Gout Treatment in Office-based Outpatient Care from 2009- 2016
Background/Purpose: Studies show that gout treatment remains suboptimal in the United States (US). Despite clear benefits for urate-lowering therapy (ULT) for chronic gout, surveyed physicians…Abstract Number: 2133 • 2019 ACR/ARP Annual Meeting
Acute Myocardial Infarction in Rheumatoid Arthritis, Gout, and Osteoarthritis: A Retrospective Study Using the National Inpatient Sample from 2002-2016
Background/Purpose: Inflammation is a risk factor in the development of cardiovascular disease. The proposed etiology centers around accelerated atherosclerosis involving various cytokines in the TNF…Abstract Number: 2732 • 2019 ACR/ARP Annual Meeting
The Relationship Between Gout and Cardiovascular Disease Outcomes: A Health Data Linkage Study of 1 Million New Zealanders Using Population-level Cardiovascular Risk Prediction Equations
Background/Purpose: Some studies have reported that gout is an independent risk factor for cardiovascular events. Furthermore, urate-lowering therapy such as allopurinol may be associated with…Abstract Number: 2755 • 2019 ACR/ARP Annual Meeting
Assessing the Sensitivity to Change of the OMERACT Ultrasound Structural Gout Lesions During Urate-Lowering Therapy
Background/Purpose: To evaluate the sensitivity to change of ultrasound (US) structural gout lesions, as defined by the OMERACT US group, in gout patients during urate…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »